Overview

Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer

Status:
Not yet recruiting

Trial end date:
2025-02-01

Target enrollment:

Participant gender:

Summary

The study design will be a single arm phase 2 study in patients who have progressed on immunotherapy and who are candidates to continue pembrolizumab. Prior to enrollment in the Phase II portion, a run-in study will be performed to ensure safety and tolerability of the combination of pembrolizumab and lutetium Lu 177 dotatate. Peptide receptor radionuclide therapy (PRRT) will be given every 2 months for 4 doses. Pembrolizumab will be given every 6 weeks at 400mg fixed dosing for up to 2 years, until disease progression, or unacceptable toxicity.

Phase:

Phase 2

Details

Lead Sponsor:

Pashtoon M. Kasi

Collaborators:

GI Research Foundation
Merck Sharp & Dohme LLC
Novartis

Treatments:

Lutetium Lu 177 dotatate
Pembrolizumab